Names | |
---|---|
IUPAC name 2-{(2--2-oxido-1,3,2-oxazaphosphinan-4-yl}thio)ethanesulfonic acid | |
Other names 2-{-2-oxo-1-oxa-3-aza-2λ-phosphacyclohex-4-yl}sulfanyl]ethanesulfonic acid | |
Identifiers | |
CAS Number | |
3D model (JSmol) | |
ChemSpider | |
MeSH | Mafosfamide |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
InChI
| |
SMILES
| |
Properties | |
Chemical formula | C9H19Cl2N2O5PS2 |
Molar mass | 401.269 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N verify (what is ?) Infobox references |
Mafosfamide (INN) is an oxazaphosphorine (cyclophosphamide-like) alkylating agent under investigation as a chemotherapeutic. It is metabolized by cytochrome P450 into 4-hydroxycyclophosphamide, which is then converted into aldophosphamide, which, in turn yields the cytotoxic metabolites phosphoramide mustard and acrolein.
Several Phase I trials have been completed.
References
- Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des. 1999 Aug;5(8):627-43. PMID 10469895
- "Intrathecal Mafosfamide". ClinicalTrials.gov. U.S. National Institutes of Health. August 21, 2006. Retrieved 2007-07-13. ClinicalTrials.gov Identifier NCT00062881.
- "Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors". ClinicalTrials.gov. U.S. National Institutes of Health. February 20, 2007. Retrieved 2007-07-13. ClinicalTrials.gov Identifier NCT00031928.
This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |